Trazodon w praktyce lekarzy rodzinnych Review article
Article Sidebar
Main Article Content
Abstract
There are no common algorithms for antidepressive therapy in Poland. Because of that antidepressive treatment depends mostly on clinical experience of physicians who choose the most safe medicines. Trazodone, classified as SARI compound (serotonin antagonist and reuptake inhibitor) differs pharmacologically from typical selective serotonin- -reuptake inhibitors (SSRIs), showing high clinical efficacy in the treatment of depression but with a more favorable adverse effect profile in many aspects than other antidepressants. Specifically, trazodone improves insomnia, anxiety and sexual dysfunctions. It is safe in elderly patients. The clinical position of trazodone is well-established in practice among physicians in Poland, as the main, safe alternative for SSRI-class antidepressant therapy.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14: 536-546.
3. ChPL. Charakterystyka produktu leczniczego. 07.02.2012 .
4. Ather SA, Ankier SI, Middleton RSW. A double-blind evaluation of trazodone in the treatment of depression in the elderly. Brit J Clin Pract 1985; 39(5): 192-199.
5. FDA. Food and Drug Administration. Online.
6. Rettman KS, McClintock C. Hepatotoxicity after short-term trazodone therapy. Ann Pharmacother 2001; 35(12): 1559-1561.
7. Altamura AC, Mauri MC, Rudas N et al. Clinical activity and tolerability of trazodone, mianserin and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol 1989; 12(supl 1): 25-37.
8. Baldwin DS, Evans DL, Hirschfeld RM, Kasper S. Can we distinguish anxiety from depression? Psychopharmacol Bull 2002; 36(supl 2): 158-165.
9. Łoza B, Polikowska M. Zespół cywilizacyjny. Nowe rozpoznanie i nowe metody oddziaływań terapeutycznych. Neuropsychiatria. Przegląd Kliniczny 2015; 7(3): 110-120.
10. Shigemoto Y, Fujii Y, Shinomiya K, Kamei C. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res 2004; 1023: 121-125.
11. Oberndorfer S, Saletu-Zychlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiol 2000; 42: 69-78.
12. Le Bon O. Contribution of sleep research to the development of new antidepressants. Dialog Clin Neurosc 2005; 7: 305-313.
13. Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double blind placebo-controlled study in healthy adults. J Clin Psychiatry 1990; 51: 18-22.
14. Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy In Psychiatry: A Review. Mens Sana Monogr 2013; 11(1): 82-99.
15. Plaskota A. Leki psychiatryczne dla seniorów 75+ w Polsce. Neuropsychiatria. Przegląd Kliniczny 2016; 9(3): 90-94.
16. Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987; 144(6): 785-787.
17. Prasad A. Efficacy of trazodone as an anti-obsessional agent. Pharmacol Biochem Behav 1985; 22(2): 347-348.
18. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001; 34(4): 128-131.
19. Rickels K, Downing R, Schweizer E. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884-895.
20. Morillas-Arques P, Rodriguez-Lopez C, Molina-Barea R et al. Trazodone for the treatment of fibromyalgia: An open-label, 12-week study. BMC Musculoskeletal Disorders 2010; 11: 204.
21. Pope HG, Keck PE, McElroy SL, Hudson JI. A placebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989; 9(4): 254-259.
22. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010; 197(3): 174-179.
23. Weisler RH, Johnston JA, Linberry CG et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994; 14(3): 170-179.
24. Le Bon O, Murphy JR, Staner L et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol 2003; 23(4): 377-383.
25. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU International 2003; 92(4): 441-446.